Mesenchymal Cell News Volume 5.10 | Mar 19 2013

The Critical Role of Extracellular Matrix Proteins within the Human MSC Niche in Endothelial Differentiation
Scientists investigated the endothelial differentiation capacity of mesenchymal stem cells (MSCs) derived from bone tissue. They found that fetal pre-osteoblast and adult trabecular bone-derived MSCs express similar surface markers as bone marrow MSCs and can differentiate into adipocytes, osteoblasts, and chondrocytes. [Biomaterials] Abstract

Mesenchymal Stem Cells Ameliorate Experimental Peritoneal Fibrosis by Suppressing Inflammation and Inhibiting Transforming Growth Factor-β1 Signaling
Since peritoneal fibrosis is a serious complication of peritoneal dialysis, researchers tested whether mesenchymal stem cells suppress this using a chlorhexidine gluconate model in rats. [Kidney Int] Full Article

Cell Size and Velocity of Injection Are Major Determinants of the Safety of Intracarotid Stem Cell Transplantation
Glial-restricted precursors and mesenchymal stem cells were transplanted into the internal carotid artery of rats, using a microcatheter. Magnetic resonance imaging was used to detect post-transplantation complications, including the development of stroke, for the following experimental variables: cell size, cell dose, cell infusion velocity, delay between artery occlusion and cell infusion, discordant versus concordant xenografting, and intracarotid transplantation with preserved versus compromised blood flow. [J Cereb Blood Flow Metab] Abstract

High Aminopeptidase N/CD13 Levels Characterize Human Amniotic Mesenchymal Stem Cells and Drive Their Increased Adipogenic Potential in Obese Women
Researchers enrolled 16 obese and 7 normal weight control-women at delivery and 32 not pregnant women. Human amniotic mesenchymal stem cells were phenotyped by flow cytometry; several maternal and newborn clinical and biochemical parameters were also measured. [Stem Cell Dev] Abstract

Priming Mesenchymal Stem Cells Boosts Stem Cell Therapy to Treat Myocardial Infarction
Investigators showed that priming mesenchymal stem cells towards cardiomyogenic lineage enhances their beneficial effects in vivo as a treatment option for acute phase myocardial infarction. [J Cell Mol Med]
Full Article

Mesenchymal Stem Cells Derived from Adipose Tissue vs Bone Marrow: In Vitro Comparison of Their Tropism towards Gliomas
Commercial and primary culture adipose-derived mesenchymal stem cells (AMSCs) and commercial bone marrow-derived mesenchymal stem cells (BMSCs) demonstrated no statistically significant difference in their migration towards glioma conditioned media in vitro. There was statistically significant difference in the proliferation rate of both commercial AMSCs and BMSCs as compared to primary culture AMSCs, suggesting primary cultures have a slower growth rate than commercially available cell lines. [PLoS One]
Full Article | Press Release

Large-Scale Expansion of Pre-Isolated Bone Marrow Mesenchymal Stromal Cells in Serum-Free Conditions
Researchers screened five different commercially available serum-free media for their ability to support the growth and expansion of pre-isolated undifferentiated bone marrow-derived mesenchymal stromal or stem cells and compared the results with cells grown in standard fetal bovine serum-containing medium as control. [J Tissue Eng Regen Med] Abstract

The Effects of Inhibiting Hedgehog Signaling Pathways by Using Specific Antagonist Cyclopamine on the Chondrogenic Differentiation of Mesenchymal Stem Cells
Researchers investigated the effects of cyclopamine, a specific inhibitor of Hedgehog signaling pathways, on the chondrogenic differentiation of mesenchymal stem cells. [Int J Mol Sci] Abstract | Full Article

Increased In Vivo Angiogenic Effect of Glioma Stromal Mesenchymal Stem-Like Cells on Glioma Cancer Stem Cells from Patients with Glioblastoma
Scientists investigated the biological effects of glioma stromal mesenchymal stem-like cells (GS-MSLCs) on glioma cancer stem cells (gCSCs), testing the hypothesis that GS-MSLCs alter the biological characteristics of gCSCs. [Int J Oncol] Abstract

Three Years after Transplants in Human Mandibles, Histological and In-Line Holotomography Revealed that Stem Cells Regenerated a Compact Rather than a Spongy Bone: Biological and Clinical Implications
Mesenchymal stem cells deriving from dental pulp differentiate into osteoblasts capable of producing bone. In previous studies, the authors extensively demonstrated that, when seeded on collagen I scaffolds, these cells can be conveniently used for the repair of human mandible defects. Here, they assessed the stability and quality of the regenerated bone and vessel network three years after the grafting intervention, with conventional procedures and in-line holotomography, an advanced phase-imaging method using synchrotron radiation that offers improved sensitivity toward low-absorbing structures. [Stem Cells Transl Med]
Abstract | Press Release

REVIEWS

Phase II ALS Clinical Trial with BrainStorm Cell Therapeutics’ NurOwn™ to Be Expanded to a Third Premiere U.S. Clinical Site
BrainStorm Cell Therapeutics announced that Mayo Clinic in Rochester, Minnesota has entered into a Memorandum of Understanding with the intent to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS). [BrainStorm Cell Therapeutics, Inc.] Press Release

NeoStem Announces Intellectual Property Expansion in Cardiovascular Disease
NeoStem, Inc. announced that Amorcyte, LLC, its wholly owned subsidiary, received a Notice of Allowance of claims from the U.S. Patent and Trademark office for patent application 13/285,606 covering a method of treating a progressive myocardial injury caused by an ischemic condition and utilizing a multi-dosing regimen. Once granted, this will represent Amorcyte’s fourth U.S. patent and sixth patent overall. [NeoStem, Inc.]
Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW ICCSCE 2013: International Conference on Cell and Stem Cell Engineering
September 26-27, 2013
Rome, Italy

Visit our events page to see a complete list of events in the mesenchymal cell community.

Full Professorship – Stem Cell Biology (Helmholtz Zentrum Munchen)

Postdoctoral Position – Dysregulation of Hematopoietic and Mesenchymal Stem Cells (Indiana University)

Lecturer or Reader – Associate Professor (University of Reading)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Positions – Angiogenesis and Human Mesenchymal Stem Cell Biology (Boston University)

Postdoctoral Position – Stem Cell Development (Stony Brook University)

Postdoctoral Position – Inflammation and Fibrosis (Institut Pasteur)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.